載入中
NASDAQHealthcareBiotechnology
最新資料
US$9.08
−US$0.14 · -1.52%
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
前收盤價
US$9.08
−US$0.14 · -1.52%
盤中時間採用ET。市場資料可能有所延遲。
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
日內區間
目前US$9.08
52週區間
目前US$9.08
盤中時間採用ET。市場資料可能有所延遲。
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
日內區間
目前US$9.08
52週區間
目前US$9.08
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 研究與開發 | 4887.7萬 EUR | 3931萬 EUR | 2631.1萬 EUR | 1942.1萬 EUR |
| 銷售、一般及管理費用 | 1257.2萬 EUR | 982.2萬 EUR | 599.7萬 EUR | 449萬 EUR |
| 營業費用 | 5927.5萬 EUR | 4802.1萬 EUR | 3119萬 EUR | 2263.4萬 EUR |
| 利息收入 | 160.9萬 EUR | 121.8萬 EUR | 24.5萬 EUR | 7.1萬 EUR |
| 利息支出 | 6萬 EUR | 6.7萬 EUR | 3.1萬 EUR | 4.5萬 EUR |
| 折舊和攤銷 | 21.9萬 EUR | 31.1萬 EUR | 9.9萬 EUR | 2.3萬 EUR |
| 營業利益 | −5927.5萬 EUR | −4802.1萬 EUR | −3119萬 EUR | −2263.4萬 EUR |
| 淨利 | −6254.7萬 EUR | −4626.7萬 EUR | −1139萬 EUR | −814.2萬 EUR |
公司資料更新於 2026年10月11日。
近期已公布業績
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
